Rexahn partners with Merck on combo study in TNBC
The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.
The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company